Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design and Population
2.2. Data Collection
2.3. Isolation of H. pylori Strains and Growth Conditions
2.4. Antimicrobial Susceptibility Testing
2.5. Eradication Therapy for H. pylori
2.6. Statistical Analysis
3. Results
3.1. Flow Chart and Baseline Characteristics
3.2. Results of Antimicrobial Susceptibility Testing
3.3. Eradication Rate for H. pylori
3.4. Comparison between Antimicrobial Susceptibility Testing and Eradication Rate
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
Appendix A
Antimicrobial Susceptibility Testing | Number (%) of Successful Eradications | ||
---|---|---|---|
Clarithromycin | Amoxicillin | Metronidazole | |
S | S | S | 23/24 (95.8) |
S | R | S | 3/3 (100.0) |
S | S | R | 8/9 (88.9) |
S | R | R | 0/0 |
R | S | S | 2/4 (50.0) |
R | R | S | 1/2 (50.0) |
R | S | R | 0/0 |
R | R | R | 0/1 (0.0) |
References
- Correa, P. Helicobacter pylori and gastric carcinogenesis. Am. J. Surg. Pathol. 1995, 19, S37–S43. [Google Scholar] [PubMed]
- Park, Y.M.; Kim, J.H.; Baik, S.J.; Park, J.J.; Youn, Y.H.; Park, H. Clinical risk assessment for gastric cancer in asymptomatic population after a health check-up: An individualized consideration of the risk factors. Medicine 2016, 95, e5351. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.M.; Kim, J.H.; Baik, S.J.; Chun, J.; Youn, Y.H.; Park, H. Sarcopenia and sarcopenic obesity as novel risk factors for gastric carcinogenesis: A health checkup cohort study. Front. Oncol. 2019, 9, 1249. [Google Scholar] [CrossRef] [PubMed]
- Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; et al. Global prevalence of helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology 2017, 153, 420–429. [Google Scholar] [CrossRef] [Green Version]
- Gong, E.; Yun, S.; Jung, H.; Lim, H.; Choi, K.; Ahn, J.; Lee, J.; Kim, D.; Choi, K.; Song, H.; et al. Meta-analysis of first-line triple therapy for helicobacter pylori eradication in korea: Is it time to change? Helicobacter 2014, 29, 704–713. [Google Scholar] [CrossRef] [Green Version]
- Kim, S.G.; Jung, H.K.; Lee, H.L.; Jang, J.Y.; Lee, H.; Kim, C.G.; Shin, W.G.; Shin, E.S.; Lee, Y.C.; Korean College of Helicobacter and Upper Gastrointestinal Research; et al. Guidelines for the diagnosis and treatment of helicobacter pylori infection in korea, 2013 revised edition. J. Gastroenterol. Hepatol. 2014, 29, 1371–1386. [Google Scholar] [CrossRef]
- O’Connor, J.P.; Taneike, I.; O’Morain, C. Improving compliance with helicobacter pylori eradication therapy: When and how? Ther. Adv. Gastroenterol. 2009, 2, 273–279. [Google Scholar] [CrossRef] [Green Version]
- Savoldi, A.; Carrara, E.; Graham, D.Y.; Conti, M.; Tacconelli, E. Prevalence of antibiotic resistance in helicobacter pylori: A systematic review and meta-analysis in world health organization regions. Gastroenterology 2018, 155, 1372–1382.e17. [Google Scholar] [CrossRef] [Green Version]
- Lee, K.H.; Park, S.Y.; Jeong, S.J.; Jung, D.H.; Kim, J.H.; Jeong, S.H.; Kang, I.M.; Song, Y.G. Can aminoglycosides be used as a new treatment for helicobacter pylori? In vitro activity of recently isolated isolated helicobacter pylori. Infect. Chemother. 2019, 51, 10–20. [Google Scholar] [CrossRef]
- Khan, Z.A.; Siddiqui, M.F.; Park, S. Current and emerging methods of antibiotic susceptibility testing. Diagnostics 2019, 9, 49. [Google Scholar] [CrossRef] [Green Version]
- Lehours, P.; Siffre, E.; Megraud, F. Dpo multiplex pcr as an alternative to culture and susceptibility testing to detect helicobacter pylori and its resistance to clarithromycin. BMC Gastroenterol. 2011, 11, 112. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jung, D.H.; Kim, J.H.; Jeong, S.J.; Park, S.Y.; Kang, I.M.; Lee, K.H.; Song, Y.G. Peptide nucleic acid probe-based analysis as a new detection method for clarithromycin resistance in helicobacter pylori. Gut. Liver. 2018, 12, 641–647. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Gisbert, J.P.; Kuipers, E.J.; Axon, A.T.; Bazzoli, F.; Gasbarrini, A.; Atherton, J.; Graham, D.Y.; et al. Management of helicobacter pylori infection-the maastricht v/florence consensus report. Gut 2017, 66, 6–30. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Malfertheiner, P.; Megraud, F.; O’Morain, C.A.; Atherton, J.; Axon, A.T.; Bazzoli, F.; Gensini, G.F.; Gisbert, J.P.; Graham, D.Y.; Rokkas, T.; et al. Management of helicobacter pylori infection--the maastricht iv/florence consensus report. Gut 2012, 61, 646–664. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Selgrad, M.; Meissle, J.; Bornschein, J.; Kandulski, A.; Langner, C.; Varbanova, M.; Wex, T.; Tammer, I.; Schluter, D.; Malfertheiner, P. Antibiotic susceptibility of helicobacter pylori in central germany and its relationship with the number of eradication therapies. Eur. J. Gastroenterol. Hepatol. 2013, 25, 1257–1260. [Google Scholar] [CrossRef]
- Nahar, S.; Mukhopadhyay, A.K.; Khan, R.; Ahmad, M.M.; Datta, S.; Chattopadhyay, S.; Dhar, S.C.; Sarker, S.A.; Engstrand, L.; Berg, D.E.; et al. Antimicrobial susceptibility of helicobacter pylori strains isolated in bangladesh. J. Clin. Microbiol. 2004, 42, 4856–4858. [Google Scholar] [CrossRef] [Green Version]
- Chey, W.D.; Leontiadis, G.I.; Howden, C.W.; Moss, S.F. Correction: Acg clinical guideline: Treatment of helicobacter pylori infection. Am. J. Gastroenterol. 2018, 113, 1102. [Google Scholar] [CrossRef]
- Cederbrant, G.; Kahlmeter, G.; Ljungh, A. The e test for antimicrobial susceptibility testing of helicobacter pylori. J. Antimicrob. Chemother. 1993, 31, 65–71. [Google Scholar] [CrossRef]
- Alarcon, T.; Urruzuno, P.; Martinez, M.J.; Domingo, D.; Llorca, L.; Correa, A.; Lopez-Brea, M. Antimicrobial susceptibility of 6 antimicrobial agents in helicobacter pylori clinical isolates by using eucast breakpoints compared with previously used breakpoints. Enferm. Infecc. Microbiol. Clin. 2017, 35, 278–282. [Google Scholar] [CrossRef]
- Chen, H.; Dang, Y.; Zhou, X.; Liu, B.; Liu, S.; Zhang, G. Tailored therapy versus empiric chosen treatment for helicobacter pylori eradication: A meta-analysis. Medicine 2016, 95, e2750. [Google Scholar] [CrossRef]
- Kobayashi, I.; Murakami, K.; Kato, M.; Kato, S.; Azuma, T.; Takahashi, S.; Uemura, N.; Katsuyama, T.; Fukuda, Y.; Haruma, K.; et al. Changing antimicrobial susceptibility epidemiology of helicobacter pylori strains in japan between 2002 and 2005. J. Clin. Microbiol. 2007, 45, 4006–4010. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kwon, Y.H.; Kim, N.; Lee, J.Y.; Choi, Y.J.; Yoon, K.; Nam, R.H.; Suh, J.H.; Lee, J.W.; Lee, D.H. Comparison of the efficacy of culture-based tailored therapy for helicobacter pylori eradication with that of the traditional second-line rescue therapy in korean patients: A prospective single tertiary center study. Scand. J. Gastroentero. 2016, 51, 270–276. [Google Scholar] [CrossRef] [PubMed]
- Furuta, T.; Shirai, N.; Kodaira, M.; Sugimoto, M.; Nogaki, A.; Kuriyama, S.; Iwaizumi, M.; Yamade, M.; Terakawa, I.; Ohashi, K.; et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of h-pylori. Clin. Pharm. 2007, 81, 521–528. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Ahn, J.Y.; Choi, K.D.; Jung, H.Y.; Kim, J.M.; Baik, G.H.; Kim, B.W.; Park, J.C.; Jung, H.K.; Cho, S.J.; et al. Nationwide antibiotic resistance mapping of helicobacter pylori in korea: A prospective multicenter study. Helicobacter 2019, 24, e12592. [Google Scholar] [CrossRef]
- Peters, D.H.; Clissold, S.P. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992, 44, 117–164. [Google Scholar] [CrossRef]
- Kim, J.M.; Mm, J.S.; Jung, H.C.; Kim, N.; Kim, Y.J.; Song, I.S. Distribution of antibiotic mics for helicobacter pylori strains over a 16-year period in patients from seoul, south korea. Antimicrob. Agents Ch. 2004, 48, 4843–4847. [Google Scholar] [CrossRef] [Green Version]
- Kim, J.M.; Kim, J.S.; Jung, H.C.; Kim, N.; Song, I.S. Antibiotic resistance of helicobacter pylori isolated from korean patients in 2003. Korean. J. Gastroenterol. 2004, 44, 126–135. [Google Scholar]
- Park, J.Y.; Dunbar, K.B.; Mitui, M.; Arnold, C.A.; Lam-Himlin, D.M.; Valasek, M.A.; Thung, I.; Okwara, C.; Coss, E.; Cryer, B.; et al. Helicobacter pylori clarithromycin resistance and treatment failure are common in the USA. Dig. Dis. Sci. 2016, 61, 2373–2380. [Google Scholar] [CrossRef]
- Lee, J.H.; Shin, J.H.; Roe, I.H.; Sohn, S.G.; Lee, J.H.; Kang, G.H.; Lee, H.K.; Jeong, B.C.; Lee, S.H. Impact of clarithromycin resistance on eradication of helicobacter pylori in infected adults. Antimicrob. Agents. Ch. 2005, 49, 1600–1603. [Google Scholar] [CrossRef] [Green Version]
- Hsieh, P.F.; Yang, J.C.; Lin, J.T.; Wang, J.T. Molecular mechanisms of clarithromycin resistance in helicobacter pylori. J. Med. Assoc. 1998, 97, 445–452. [Google Scholar]
- Marais, A.; Bilardi, C.; Cantet, F.; Mendz, G.L.; Megraud, F. Characterization of the genes rdxa and frxa involved in metronidazole resistance in helicobacter pylori. Res. Microbiol. 2003, 154, 137–144. [Google Scholar] [CrossRef]
- Lee, S.M.; Kim, N.; Kwon, Y.H.; Nam, R.H.; Kim, J.M.; Park, J.Y.; Lee, Y.S.; Lee, D.H. Rdxa, frxa, and efflux pump in metronidazole-resistant helicobacter pylori: Their relation to clinical outcomes. J. Gastroen. Hepatol. 2018, 33, 681–688. [Google Scholar] [CrossRef] [PubMed]
- Kim, J.M.; Kim, J.S.; Kim, N.; Kim, S.G.; Jung, H.C.; Song, I.S. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for helicobacter pylori isolated from korean patients. Int. J. Antimicrob. Agents 2006, 28, 6–13. [Google Scholar] [CrossRef] [PubMed]
- Smith, S.M.; O’Morain, C.; McNamara, D. Antimicrobial susceptibility testing for helicobacter pylori in times of increasing antibiotic resistance. World. J. Gastroentero. 2014, 20, 9912–9921. [Google Scholar] [CrossRef] [PubMed]
- Alarcon, T.; Lopez-Brea, M. Detection of helicobacter pylori and the resistance to clarithromycin in gastric biopsies obtained from pediatric patients by real time pcr. Helicobacter 2007, 12, 460. [Google Scholar]
- Lottspeich, C.; Schwarzer, A.; Panthel, M.; Koletzko, S.; Russmann, H. Evaluation of the novel helicobacter pylori clarires real-time pcr assay for detection and clarithromycin susceptibility testing of h-pylori in stool specimens from symptomatic children. J. Clin. Microbiol. 2007, 45, 1718–1722. [Google Scholar] [CrossRef] [Green Version]
- Clinical and Laboratory Standards Institute. Methods for Antimicrobial Dilution and Disk Susceptibility testing of Infrequently Isolated or Fastidious Bacteria, 3rd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA, 2016; p. xviii. 98p. [Google Scholar]
- Boyanova, L.; Hadzhiyski, P.; Kandilarov, N.; Markovska, R.; Mitov, I. Multidrug resistance in helicobacter pylori: Current state and future directions. Expert Rev. Clin. Pharm. 2019, 12, 909–915. [Google Scholar] [CrossRef]
- Kwon, D.H.; Dore, M.P.; Kim, J.J.; Kato, M.; Lee, M.; Wu, J.Y.; Graham, D.Y. High-level beta-lactam resistance associated with acquired multidrug resistance in helicobacter pylori. Antimicrob. Agents. Chemother. 2003, 47, 2169–2178. [Google Scholar] [CrossRef] [Green Version]
- Saeed, A.; Bosch, A.; Bettiol, M.; Nossa Gonzalez, D.L.; Erben, M.F.; Lamberti, Y. Novel guanidine compound against multidrug-resistant cystic fibrosis-associated bacterial species. Molecules 2018, 23, 1158. [Google Scholar] [CrossRef] [Green Version]
Characteristics | All Patients (n = 247) |
---|---|
Age (years, mean ± SD) | 55.4 ± 11.8 |
Male (n, %) | 106 (42.9) |
Height (cm, mean ± SD) | 163.2 ± 8.4 |
Weight (kg, mean ± SD) | 64.1 ± 12.2 |
BMI (kg/m2, mean ± SD) | 23.3 ± 3.4 |
Current smoker (n, %) | 45 (18.2) |
Alcohol history (n, %) | 103 (41.7) |
Diabetes mellitus (n, %) | 50 (20.2) |
Hypertension (n, %) | 24 (9.7) |
RUT, positive (n, %) | 223 (90.3) |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, Y.M.; Lee, K.H.; Kim, J.-H.; Park, S.Y.; Song, Y.G.; Jeon, S.Y.; Park, H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics 2020, 9, 589. https://doi.org/10.3390/antibiotics9090589
Kim YM, Lee KH, Kim J-H, Park SY, Song YG, Jeon SY, Park H. Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics. 2020; 9(9):589. https://doi.org/10.3390/antibiotics9090589
Chicago/Turabian StyleKim, Young Min, Kyoung Hwa Lee, Jie-Hyun Kim, Soon Young Park, Young Goo Song, Se Yeon Jeon, and Hyojin Park. 2020. "Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori?" Antibiotics 9, no. 9: 589. https://doi.org/10.3390/antibiotics9090589
APA StyleKim, Y. M., Lee, K. H., Kim, J. -H., Park, S. Y., Song, Y. G., Jeon, S. Y., & Park, H. (2020). Is Only Clarithromycin Susceptibility Important for the Successful Eradication of Helicobacter pylori? Antibiotics, 9(9), 589. https://doi.org/10.3390/antibiotics9090589